4//SEC Filing
Levin Andrew David 4
Accession 0000950170-25-082321
CIK 0001768446other
Filed
Jun 4, 8:00 PM ET
Accepted
Jun 5, 4:10 PM ET
Size
22.0 KB
Accession
0000950170-25-082321
Insider Transaction Report
Form 4
Climb Bio, Inc.CLYM
Levin Andrew David
Director
Transactions
- Award
Stock Option (Right to Buy)
2025-06-04+40,000→ 40,000 totalExercise: $1.29Exp: 2035-06-03→ Common Stock (40,000 underlying)
Footnotes (2)
- [F1]The shares subject to the option will vest on the earlier of June 4, 2026 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date.
- [F2]Under the reporting person's arrangement with RA Capital Management, L.P. (the "Adviser"), the reporting person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The reporting person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account to the Adviser. The reporting person therefore disclaims beneficial ownership of the stock option and underlying common stock.
Documents
Issuer
Climb Bio, Inc.
CIK 0001768446
Entity typeother
Related Parties
1- filerCIK 0001867539
Filing Metadata
- Form type
- 4
- Filed
- Jun 4, 8:00 PM ET
- Accepted
- Jun 5, 4:10 PM ET
- Size
- 22.0 KB